TGFBR2 and non-small cell lung carcinoma: When the data was analyzed based on TGFβR2 expression as well as treatment status, OS and DFS time was found to be significantly longer in treated NSCLC patients with low expression of TGFβR2 as opposed to untreated patients with high expression (40.70 ± 2.07 vs. 24.23 ± 1.25, P = 0.002 and 36.53 ± 2.97 vs. 21.33 ± 1.34, P < 0.001) (Table 4).